A pharmaceutical company that develops and markets drugs targeting cortisol regulation, including Korlym for Cushing's syndrome and related pipeline candidates.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Bridgewater | 56 | Added +50% | 57,602 | $5,008,494 | 0.0% |
| Paul Tudor Jones / Tudor | 63 | Trimmed -54% | 25,200 | $2,191,140 | 0.0% |
| Steve Cohen / Point72 | 76 | Trimmed -82% | 10,100 | $878,195 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-09-24.